Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.56 |
| ▸ | HTR7 | P34969 | 11/20 | 0.56 |
| ▸ | DRD2 | P14416 | 9/20 | 0.55 |
| ▸ | HTR6 | P50406 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83163 | 0.83 | HTR1A (0.63) | HTR1AHTR7DRD2HTR6DRD3 | |
| SCHEMBL88226 | 0.81 | HTR1A (0.45) | HTR1ADRD2ACHEDRD3HTR2A | |
| SCHEMBL82842 | 0.79 | DRD2 (0.73) | HTR1ADRD2DRD3 | |
| SCHEMBL3074410 | 0.79 | DRD2 (0.73) | HTR1ADRD2DRD3 | |
| SCHEMBL82749 | 0.78 | DRD2 (0.72) | HTR1ADRD2DRD3 | |
| SCHEMBL3073890 | 0.78 | DRD2 (0.72) | HTR1ADRD2DRD3 | |
| SCHEMBL82104 | 0.78 | DRD2 (0.72) | HTR1ADRD2DRD3 | |
| SCHEMBL3086811 | 0.78 | DRD2 (0.72) | HTR1ADRD2DRD3 | |
| SCHEMBL82168 | 0.77 | KCNH2 (0.49) | HTR1AACHEDRD3HTR2A | |
| SCHEMBL3090272 | 0.77 | DRD2 (0.65) | HTR1AHTR7DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | claimed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | HTR1A 3335/4885HTR7 3976/4885DRD2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.